Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to BTK inhibition, the phase I/II BRUIN study showed. Among 247 patients who had previously received a covalent BTK inhibitor, 73.3% (95% CI 67.3-78.7) achieved an overall […]
Michael Wang on the Reversible BTK Inhibitor for Previously Treated MCL
The FDA recently granted accelerated approval to pirtobrutinib (Jaypirca), a reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor. In this exclusive MedPage Today video, Michael Wang, MD, of the University of Texas MD […]
Opinion | Physicians Can Kick Tech’s A** Right Back
Physicians are getting their asses kicked by technology, but this is reversible if they integrate technology as they do laboratory science. Medicine needs specialized doctors who only focus on technology. This will combat burnout and take control of a system that has no other incentive to adapt to clinical needs. In 2013, I graduated medical […]